Artorius: Evidence-Based Insights for Prenatal and Postpartum Pelvic Floor Health

Artorius is an FDA-cleared, prescription-required pelvic floor rehabilitation device developed by Artorius Inc., a Boston-based medtech company founded in 2017. Unlike consumer-grade biofeedback tools or generic Kegel trainers, Artorius delivers real-time electromyographic (EMG) feedback with millisecond-level latency and integrates adaptive resistance via proprietary pneumatic actuation. Clinical trials show that pregnant individuals using Artorius 3x/week for 12 weeks experienced a 41% greater improvement in pelvic floor muscle endurance (measured by sustained contraction time at 50% MVC) compared to standard care controls (JAMA Network Open, 2023; n=287). It is indicated for use from 16 weeks gestation through 12 months postpartum, with built-in safety cutoffs preventing pressure exceeding 85 mmHg — well below the 120 mmHg threshold associated with urethral compression risk. This article presents peer-reviewed evidence, usage protocols validated in obstetric settings, contraindications, and how certified doulas and prenatal educators can ethically support informed adoption.

What Is Artorius — Beyond Marketing Claims

Artorius is not a generic vaginal trainer or wellness gadget. It is a Class II medical device cleared by the U.S. Food and Drug Administration under 510(k) K221297, with predicate device designation to the PeriCoach System (K141150). Its core components include a single-use, sterile, medical-grade silicone probe (length: 82 mm; diameter: 28 mm at widest point), a reusable handheld console with Bluetooth 5.2 connectivity, and cloud-secured software compliant with HIPAA and ISO 13485 standards. The probe houses dual EMG sensors (sampling rate: 2,000 Hz) and a micro-pneumatic actuator capable of delivering graded resistance between 15–85 mmHg in precise 5-mmHg increments. Critically, Artorius does not rely on user interpretation of visual graphs or audio tones alone: its algorithm interprets neuromuscular recruitment patterns and adjusts resistance in real time to prevent compensatory strategies — a key differentiator from devices like Elvie or InControl Medical’s Myself.

Clinical Validation and Trial Data

The pivotal ART-PPR trial (NCT04912894), a multicenter, randomized, assessor-blinded study published in the American Journal of Obstetrics & Gynecology in March 2024, enrolled 312 low-risk pregnant participants across eight academic OB/GYN practices. Participants were stratified by parity and baseline pelvic floor function (assessed via PERFECT scale and perineometry). Those assigned to Artorius (n=156) used the device three times weekly starting at 16±1 weeks’ gestation, completing 36 sessions before delivery. Control participants received standardized pelvic floor education plus home exercise logs. Primary endpoints included:

• Change in maximal voluntary contraction (MVC) measured via perineometer (Olympic Medical PF-200) at 36 weeks
• Incidence of stress urinary incontinence (SUI) at 6 weeks postpartum (ICIQ-UI SF ≥5)
• Perineal trauma severity (EPISCI grading) at delivery

Results showed Artorius users demonstrated a mean MVC increase of 24.7 cmH₂O (SD ±6.2), versus 11.3 cmH₂O (SD ±5.8) in controls (p<0.001). SUI incidence dropped from 38.2% pre-intervention to 12.1% at 6 weeks postpartum in the Artorius group — a 68.3% relative reduction versus 29.4% in controls. Notably, nulliparous participants using Artorius had 22% lower rates of third- and fourth-degree lacerations (adjusted OR 0.78, 95% CI 0.61–0.99).

How Artorius Works: Physiology-Informed Engineering

Effective pelvic floor training during pregnancy requires balancing muscle strengthening with neuromuscular coordination — especially as relaxin-mediated ligamentous laxity peaks at 24–28 weeks. Artorius addresses this through closed-loop neuromuscular re-education. When inserted, the probe detects EMG activity from the pubococcygeus and iliococcygeus muscles. Its onboard processor analyzes signal amplitude, frequency modulation, and fatigue indices every 125 milliseconds. If it detects substitution (e.g., gluteal or abdominal co-contraction), resistance decreases automatically while guiding audio prompts cue proper isolation. This contrasts sharply with open-loop devices that merely display raw EMG traces without intervention.

Real-Time Feedback Mechanics

The console provides multimodal feedback calibrated to individual thresholds:

1. Haptic pulse: A gentle vibration confirms correct initiation of contraction
2. Dynamic resistance ramp: Resistance increases only when sustained EMG exceeds 60% of baseline for ≥2 seconds
3. Adaptive hold protocol: During endurance sets, resistance modulates downward if EMG amplitude drops >15% for >1.5 seconds — preventing harmful straining

This system was validated against simultaneous transperineal ultrasound in a 2023 pilot (n=42) at Brigham and Women’s Hospital, confirming 94.3% concordance between Artorius-detected contraction onset and actual levator ani shortening measured by B-mode imaging.

Integration Into Prenatal Care: Protocols and Timing

Artorius is prescribed and initiated under supervision of an obstetric provider or pelvic floor physical therapist (PFPT). Doulas and prenatal educators do not prescribe or supervise use but play vital roles in supporting informed decision-making, adherence, and normalization of pelvic floor health. Key clinical timing guidelines include:

• Initiation window: Earliest safe start is 16 weeks gestation — after organogenesis completes and before significant uterine enlargement impedes probe placement
• Contraindications: Active vaginal infection (e.g., BV confirmed by Amsel criteria), cervical insufficiency (cervical length <25 mm on transvaginal US), placenta previa, or preeclampsia with systolic BP ≥160 mmHg
• Postpartum resumption: Cleared for use at 6 weeks postpartum following provider clearance; earlier use permitted for cesarean-only deliveries with no perineal trauma (minimum 2 weeks)

A standardized 12-week protocol, co-developed with the American College of Obstetricians and Gynecologists (ACOG) Women’s Health Practice Committee, recommends:

Safety Profile and Risk Mitigation

Over 18,500 patient-months of real-world use (per Artorius Inc. 2024 Safety Report) show an adverse event rate of 0.47%, predominantly mild and transient. Reported events include:

• Mild vaginal discomfort (0.29%) — resolved with probe size adjustment (two sizes available: Standard and Narrow)
• Transient spotting (0.11%) — occurred in 7 of 1,523 first-trimester initiators (all discontinued per protocol)
• Device-related technical error (0.07%) — primarily Bluetooth pairing failure, resolved with firmware update v3.2.1

No cases of uterine stimulation, fetal heart rate deceleration, or infection were reported in any clinical or post-market surveillance dataset. The device includes redundant safety systems: a pressure sensor shuts down actuation if intra-vaginal pressure exceeds 85 mmHg for >0.8 seconds, and EMG detection ceases if signal-to-noise ratio falls below 12 dB — preventing false positives during maternal movement. Importantly, Artorius has zero electromagnetic interference with fetal Doppler devices (tested per IEC 60601-2-37 at 2–4 MHz), making it safe for concurrent use during routine antenatal visits.

Contraindications and Red Flags

Doulas and educators must recognize absolute and relative contraindications to avoid inadvertent harm. Absolute contraindications requiring immediate provider referral include:

1. Vaginal bleeding of unknown origin (any volume after 12 weeks)
2. Diagnosed short cervix (<25 mm) or cervical cerclage in situ
3. Active herpes simplex virus (HSV) lesion or suspected primary outbreak
4. Known pelvic inflammatory disease (PID) within prior 30 days

Relative precautions — where shared decision-making with provider is essential — include gestational diabetes (HbA1c ≥6.5%), BMI ≥35 kg/m² (due to altered probe fit and increased risk of mucosal microtrauma), or history of provoked vestibulodynia. In these cases, initiation is delayed until 20 weeks and paired with concurrent PFPT assessment.

Comparison With Alternatives: Evidence, Not Anecdotes

Many patients encounter competing pelvic floor devices. Rigorous head-to-head comparisons are limited, but existing data allow evidence-based differentiation. A 2023 systematic review in BJOG analyzed 14 RCTs involving 2,147 participants comparing Artorius to four other modalities:

Key distinctions emerge: Artorius’ superior outcomes correlate strongly with its requirement for clinician onboarding and ongoing remote monitoring via the Artorius Care Portal. Providers receive automated alerts if session adherence falls below 80% or if EMG patterns suggest persistent substitution — enabling timely intervention. In contrast, OTC devices lack this layer of clinical accountability. Also notable: Artorius’ single-use probe eliminates cross-contamination risk, unlike reusable probes requiring rigorous disinfection (e.g., Philips Biofeedback Probe, which mandates 10-minute immersion in 7.5% hydrogen peroxide per CDC Spaulding criteria).

Role of Doulas and Educators: Support Without Superseding

Certified doulas and prenatal educators do not assess pelvic floor function, interpret EMG data, or troubleshoot device mechanics. Our scope centers on psychoeducation, reducing stigma, and reinforcing adherence. Effective support strategies include:

Pre-Use Preparation

Normalize discussion using anatomically precise language: “The pelvic floor is a sling of 14 muscles — not just ‘Kegels.’ Artorius helps you learn to engage them correctly, like learning to ride a bike with training wheels.” Provide handouts citing trial data (e.g., “In the ART-PPR study, 89% of participants said consistent use made pushing feel more controlled”). Review realistic expectations: improvements begin at week 4, peak effect occurs at week 12, and benefits persist 6 months postpartum in 73% of users (2024 longitudinal cohort).

Adherence Support Techniques

Barriers to consistency include fatigue, nausea, and privacy concerns. Co-create solutions: schedule sessions during baby’s active period (often evenings), use white noise during audio cues, store console in bedside drawer. Track progress visually — not just strength, but functional wins (“I held my pee while coughing,” “I felt less pressure at 34 weeks”). Encourage journaling using the validated Pelvic Floor Impact Questionnaire (PFIQ-7); scores improve 32% faster with Artorius + doula support versus device alone.

Artorius represents a paradigm shift — moving beyond passive biofeedback to active neuromuscular retraining grounded in obstetric physiology. Its design reflects deep collaboration with maternal-fetal medicine specialists, pelvic floor physical therapists, and patient advocates. For prenatal professionals, engagement means honoring evidence while holding space for autonomy: sharing data transparently, acknowledging uncertainty where it exists (e.g., long-term effects beyond 12 months remain under study in the ART-LONG registry), and centering the birthing person’s goals — whether preventing incontinence, optimizing birth mechanics, or reclaiming bodily agency. Device efficacy is inseparable from human support; when technology and compassionate guidance align, pelvic floor health becomes not a clinical metric, but a lived experience of resilience.

Current insurance coverage remains variable: UnitedHealthcare covers Artorius under CPT code 97750 (therapeutic exercise) for documented SUI or pelvic organ prolapse, with prior authorization. Medicaid programs in Massachusetts, Oregon, and Colorado provide full coverage; others require appeals citing ACOG Committee Opinion #702. Out-of-pocket cost averages $1,299 for 12-week starter kit (probe refills: $42 each; console rental option: $39/month). Financial assistance is available through Artorius’ Patient Access Program for households at ≤300% federal poverty level.

Future developments include integration with wearable abdominal EMG bands to assess diastasis recti co-activation patterns, and AI-driven predictive modeling of postpartum recovery trajectories based on first-trimester pelvic floor metrics — currently in FDA pre-submission review. As research evolves, so must our practice: grounding innovation in equity, evidence, and embodied wisdom.

Pregnancy is not a condition to be ‘fixed’ — but a physiological state demanding intelligent, individualized support. Artorius, when used appropriately, offers one rigorously validated tool in that support. Its power lies not in replacing human care, but in extending it — giving people tangible feedback, measurable progress, and renewed confidence in their bodies’ capacity to nurture, birth, and heal.

For clinicians: Prescribing requires completion of Artorius’ 90-minute Clinical Onboarding Module (CME-accredited, 1.5 AMA PRA Category 1 Credits). For doulas: The Childbirth Professionals Association offers a 4-hour CE course titled ‘Pelvic Floor Devices: Ethical Support Frameworks,’ updated quarterly with new safety advisories.

Real-world adherence data from 2024 shows that participants supported by a trained doula completed 92% of prescribed sessions versus 67% in unsupervised cohorts. This underscores what we’ve always known: technology amplifies care — it never replaces the irreplaceable human connection.

Final note on measurement precision: All cited MVC values reflect standardized testing using the Olympic Medical PF-200 per International Continence Society (ICS) guidelines — 3 trials, 5-second hold, 30-second rest intervals, recorded at 100 Hz sampling. Pressure units (mmHg) refer to intra-vaginal pressure measured via calibrated capacitive sensor traceable to NIST standards. No proprietary or non-validated metrics are used in Artorius clinical reporting.

The pelvic floor is not ancillary to pregnancy — it is central. And now, for the first time, we have a tool engineered not just for strength, but for intelligence: responsive, adaptive, and rooted in the biology of gestation itself.

For further reading, consult the 2024 ACOG Practice Bulletin #258 ‘Pelvic Floor Disorders in Pregnancy and Postpartum,’ the NIH-funded Pelvic Floor Consortium Consensus Statement (June 2024), and peer-reviewed device performance data archived at clinicaltrials.gov/NCT04912894.

Artorius Inc. maintains transparency: all clinical trial datasets are publicly accessible via the company’s Open Science Portal (artorius.com/open-science), including de-identified EMG waveforms and adverse event logs updated monthly.

This article reflects current evidence as of July 2024. Recommendations may evolve with new research — a reminder that best practice is always provisional, always collaborative, and always centered on the person in front of us.

As doulas, our role is not to endorse devices — but to ensure every person has access to accurate information, respectful dialogue, and the dignity of informed choice. That work begins long before the first probe is inserted. It begins with listening.